Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Eleonora MäkeläKarolina PavicTaru VarilaUrpu SalmenniemiEliisa LöyttyniemiSrikar G NagelliTea AmmunetVeli-Matti KähäriRichard E ClarkLaura L EloVenkata Kumari BachanaboyinaClaire M LucasMaija Itälä-RemesJukka WestermarckPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
We discovered a novel variant of the oncoprotein CIP2A and its clinical relevance in predicting tyrosine kinase inhibitor therapy resistance in myeloid leukemias.